Arthur Kuan

Arthur Kuan

Chief Executive OfficeratCG Oncology· In proxies 2023–2025

Pay in FY2025+7% from the year before · CG Oncology stock +44.8% the same year

Arthur Kuan was paid $11.9M in FY2025 (Dec), up 7%. CG Oncology stock rose 44.8% that year.

Pay$100 in the stock at the end of FY24 → $145
Pay is from the Summary Compensation Table of each CG Oncology proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CG OncologyPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role +72%
  2. Chunghwa Chemical Synthesis & BiotechPublic company · 4 yr
    • Director2022 – Present · 4 yrNo stock prices for these years
  3. Allied Industrial Corp., Ltd.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?